These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1378 related articles for article (PubMed ID: 17470858)

  • 41. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
    Kobayashi Y; Komatsu Y; Yuki S; Fukushima H; Sasaki T; Iwanaga I; Uebayashi M; Okuda H; Kusumi T; Miyagishima T; Sogabe S; Tateyama M; Hatanaka K; Tsuji Y; Nakamura M; Konno J; Yamamoto F; Onodera M; Iwai K; Sakata Y; Abe R; Oba K; Sakamoto N
    Future Oncol; 2015; 11(4):617-27. PubMed ID: 25686117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
    Kang JH; Lee SI; Lim DH; Park KW; Oh SY; Kwon HC; Hwang IG; Lee SC; Nam E; Shin DB; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    J Clin Oncol; 2012 May; 30(13):1513-8. PubMed ID: 22412140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
    Koukakis R; Gatta F; Hechmati G; Siena S
    Qual Life Res; 2016 Oct; 25(10):2645-2656. PubMed ID: 27083443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
    Siena S; Peeters M; Van Cutsem E; Humblet Y; Conte P; Bajetta E; Comandini D; Bodoky G; Van Hazel G; Salek T; Wolf M; Devercelli G; Woolley M; Amado RG
    Br J Cancer; 2007 Dec; 97(11):1469-74. PubMed ID: 18040272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
    Cohenuram M; Saif MW
    Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
    Gibson TB; Ranganathan A; Grothey A
    Clin Colorectal Cancer; 2006 May; 6(1):29-31. PubMed ID: 16796788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Panitumumab for the treatment of metastatic colorectal cancer: a review.
    Del Prete M; Giampieri R; Faloppi L; Bianconi M; Bittoni A; Andrikou K; Cascinu S
    Immunotherapy; 2015; 7(7):721-38. PubMed ID: 26250414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer.
    Mano M; Humblet Y
    Nat Clin Pract Oncol; 2008 Jul; 5(7):415-25. PubMed ID: 18506165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of panitumumab in the management of metastatic colorectal cancer.
    Saif MW; Cohenuram M
    Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Panitumumab: a summary of clinical development in colorectal cancer and future directions.
    Argiles G; Dienstmann R; Elez E; Tabernero J
    Future Oncol; 2012 Apr; 8(4):373-89. PubMed ID: 22515440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.
    van Hellemond IE; Creemers GJ; van Warmerdam LJ; de Jong FA; Koornstra RH
    Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):135-41. PubMed ID: 24246276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.
    Lo L; Patel D; Townsend AR; Price TJ
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1907-24. PubMed ID: 26572750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
    Caballero-Baños M; Benitez-Ribas D; Tabera J; Varea S; Vilana R; Bianchi L; Ayuso JR; Pagés M; Carrera G; Cuatrecasas M; Martin-Richard M; Cid J; Lozano M; Castells A; García-Albéniz X; Maurel J; Vilella R
    Eur J Cancer; 2016 Sep; 64():167-74. PubMed ID: 27428073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wild-Type
    Amado RG; Wolf M; Peeters M; Van Cutsem E; Siena S; Freeman DJ; Juan T; Sikorski R; Suggs S; Radinsky R; Patterson SD; Chang DD
    J Clin Oncol; 2023 Jun; 41(18):3278-3286. PubMed ID: 37315390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.